Eagle Bay Advisors’s GSK GSK Stock Holding History

Eagle Bay Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,500	Closed	-$51.3K	–	472
2024 Q4	$51.3K	Buy	1,500 +100	+7%	+$3.6K	0.03%	328
2024 Q3	$57.8K	Hold	1,400	–	–	0.02%	417
2024 Q2	$54.4K	Buy	1,400 +100	+8%	+$4.21K	0.03%	321
2024 Q1	$56.3K	Hold	1,300	–	–	0.04%	290
2023 Q4	$48.2K	Hold	1,300	–	–	0.03%	303
2023 Q3	$47.1K	Hold	1,300	–	–	0.02%	420
2023 Q2	$46.3K	Hold	1,300	–	–	0.03%	378
2023 Q1	$46.3K	Sell	1,300 -88	-6%	-$3.08K	0.03%	400
2022 Q4	$48.8K	Buy	1,388 +700	+102%	+$23.3K	0.03%	384
2022 Q3	$20K	Buy	688 +599	+673%	+$22.7K	0.01%	513
2022 Q2	$4.83K	Buy	+89	New	+$4.91K	﹤0.01%	729
2022 Q1	–	Sell	-185	Closed	-$10K	–	576
2021 Q4	$10K	Sell	185 -185	-50%	-$9.62K	0.01%	692
2021 Q3	$18K	Buy	370 +210	+131%	+$10.5K	0.01%	632
2021 Q2	$8K	Buy	+160	New	+$7.69K	0.01%	702

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eagle Bay Advisors's GSK Position: Q1 2025 in Review

Eagle Bay Advisors sold out of GSK (GSK) in Q1 2025, closing a stake of 1,500 shares — an estimated $51.3K sold.

Eagle Bay Advisors first reported a position in GSK in Q2 2021 and held it in 14 quarters. The position peaked at $57.8K in Q3 2024. 857 funds tracked by Wall St. Rank hold GSK as of Q1 2025.

Eagle Bay Advisors reported no remaining GSK position as of Q1 2025 after selling out during the quarter.
Eagle Bay Advisors sold 1,500 GSK shares in Q1 2025, an estimated $51.3K.
Eagle Bay Advisors first reported a position in GSK in Q2 2021 and held it in 14 quarters.
Eagle Bay Advisors's GSK position peaked at $57.8K in Q3 2024.
857 funds tracked by Wall St. Rank held GSK as of Q1 2025.

Based on Eagle Bay Advisors's 13F filing for Q1 2025, filed 5 May 2025.